Dieneke Schonenberg-Meinema

Dr. Dieneke Schonenberg-Meinema


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
IFIvan Foeldvari
Ivan Foeldvari
JKJens Klotsche
Jens Klotsche
OKOzgur Kasapcopur
Ozgur Kasapcopur
AAAmra Adrovic
Amra Adrovic
MTMaria Teresa Terreri
Maria Teresa Terreri
KTKathryn Seraphin Torok
Kathryn Seraphin Torok

4 January 2022 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
NCNathalie E. Chalhoub
Nathalie E. Chalhoub
SWScott E. Wenderfer
Scott E. Wenderfer
DLDeborah M. Levy
Deborah M. Levy
KRKelly Rouster‐Stevens
Kelly Rouster‐Stevens
AAAmita Aggarwal
Amita Aggarwal
FPfor the Childhood Arthritis and Rheumatology Research Alliance Lupus Nephritis Work Group and the Pediatric Rheumatology European Society Lupus Working Party
for the Childhood Arthritis and Rheumatology Research Alliance Lupus Nephritis Work Group and the Pediatric Rheumatology European Society Lupus Working Party

3 November 2020 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
IFIvan Foeldvari
Ivan Foeldvari
JKJens Klotsche
Jens Klotsche
BHBernd Hinrichs
Bernd Hinrichs
NHNicola Helmus
Nicola Helmus
OKOzgur Kasapcopur
Ozgur Kasapcopur
KTKathryn Seraphin Torok
Kathryn Seraphin Torok

3 March 2021 in Lupus
Verified
Journal Article
Open access
PDF file
DSDieneke Schonenberg-Meinema
Dieneke Schonenberg-Meinema
SBSandy C Bergkamp
Sandy C Bergkamp
ARAmara Nassar-Sheikh Rashid
Amara Nassar-Sheikh Rashid
LALeontien B van der Aa
Leontien B van der Aa
GBGodelieve J de Bree
Godelieve J de Bree
JBJ Merlijn van Den Berg
J Merlijn van Den Berg
Objectives: For selection of high-risk systemic lupus erythematosus (SLE) patients it is necessary to obtain indicators of disease severity that predict disease damage. As in systemic sclerosis, nailfold capillary abnormalities could be such a biomarker in SLE. The primary objective of this cross-sectional study is to describe capillary abnormalities in childhood-onset SLE (cSLE) cohort (onset < 18 years) and compare them with matched healthy controls. The secondary objective is to correlate the observed capillary abnormalities with demographical variables in both cohorts and with disease-specific variables in cSLE patients. Methods: Healthy controls were matched for ethnic background, age and gender. Videocapillaroscopy was performed in eight fingers with 2-4 images per finger. Quantitative and qualitative assessments of nailfold capillaroscopy images were performed according to the definitions of the EULAR study group on microcirculation in Rheumatic Diseases. Results: Both groups (n = 41 cSLE-patients and n = 41 healthy controls) were comparable for ethnic background (p = 0.317). Counted per mm, cSLE-patients showed significantly more ‘giants’ (p = 0.032), ‘abnormal capillary shapes’ (p = 0.003), ‘large capillary hemorrhages’ (p < 0.001) and ‘pericapillary extravasations’ (p < 0.001). Combined ‘abnormal capillary shapes and pericapillary extravasations’ (in the same finger) were detected in 78% (32/41 patients). By qualitative analysis, ‘microangiopathy’ was detected in 68.3% (28/41) and a ‘scleroderma pattern’ in 17.1% (7/41) of the cSLE-patients (without scleroderma symptoms). The difference of percentage positive anti-RNP antibodies in the group with or without a scleroderma pattern was not significant (p = 0.089). The number of ‘abnormal capillary shapes per mm’ was significantly correlated with treatment-naivety. The number of ‘large pathological hemorrhages per mm’ was significantly correlated with SLEDAI score and presence of nephritis. Compared to healthy controls, ‘pericapillary extravasations’ were found in significantly higher numbers per mm (p < 0.001) as well as in percentage of patients (p < 0.001). Conclusions: Our observations confirm that giants, abnormal capillary morphology and capillary hemorrhages are also observed in cSLE, as was already known for adults with SLE. Number of capillary hemorrhages in cSLE was significantly correlated with disease activity. A high frequency and total amount of “pericapillary extravasations” was observed in cSLE patients, possibly revealing a new subtype of capillary hemorrhage that might reflect endothelial damage in these pediatric patients.

16 May 2023 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
SBS. C. Bergkamp
S. C. Bergkamp
MWM. J. Wahadat
M. J. Wahadat
ASA. Salah
A. Salah
TKT. W. Kuijpers
T. W. Kuijpers
VSV. Smith
V. Smith
DSDieneke Schonenberg-Meinema
Dieneke Schonenberg-Meinema
To perform a systematic literature review and meta-analysis on endothelial cell (EC) markers that are involved and dysregulated in systemic lupus erythematosus (SLE) in relation to disease activity, as EC dysregulation plays a major role in the development of premature atherosclerosis in SLE. Search terms were entered into Embase, MEDLINE, Web of Science, Google Scholar and Cochrane. Inclusion criteria were 1) studies published after 2000 reporting measurements of EC markers in serum and/or plasma of SLE patients (diagnosed according to ACR/SLICC criteria), 2) English language peer reviewed articles, and 3) disease activity measurement. For meta-analysis calculations, the Meta-Essentials tool by Erasmus Research Institute and of Management (ERIM) was used. Only those EC markers, which were 1) reported in at least two articles and 2) reported a correlation coefficient (i.e. Spearman’s rank or Pearson’s) between the measured levels of the EC marker and disease activity were included. For meta-analyses, a fixed effect model was used. From 2133 hits, 123 eligible articles were selected. The identified SLE-related endothelial markers were involved in EC activation, EC apoptosis, disturbed angiogenesis, defective vascular tone control, immune dysregulation and coagulopathy. Meta-analyses of primarily cross-sectional studies showed significant associations between marker levels and disease activity for the following endothelial markers: Pentraxin-3, Thrombomodulin, VEGF, VCAM-1, ICAM-1, IP-10 and MCP-1. Dysregulated EC markers without associations with disease activity were: Angiopoeitin-2, vWF, P-Selectin, TWEAK and E-Selectin. We provide a complete literature overview for dysregulated EC markers in SLE comprising a wide range of different EC functions. SLE-induced EC marker dysregulation was seen with, but also without, association with disease activity. This study provides some clarity in the eminent complex field of EC markers as biomarkers for SLE. Longitudinal data on EC markers in SLE are now needed to guide us more in unravelling the pathophysiology of premature atherosclerosis and cardiovascular events in SLE patients.

10 February 2022 in Rheumatology
Verified
Journal Article
Open access
PDF file
MWMohamed Wahadat
Mohamed Wahadat
DSDieneke Schonenberg-Meinema
Dieneke Schonenberg-Meinema
CHCornelia G van Helden-Meeuwsen
Cornelia G van Helden-Meeuwsen
STSander J van Tilburg
Sander J van Tilburg
NGNoortje Groot
Noortje Groot
MVMarjan A Versnel
Marjan A Versnel
Clinical phenotyping and predicting treatment responses in SLE patients is challenging. Extensive blood transcriptional profiling has identified various gene modules that are promising for stratification of SLE patients. We aimed to translate existing transcriptomic data into simpler gene signatures suitable for daily clinical practice. Real-time PCR of multiple genes from the IFN M1.2, IFN M5.12, neutrophil (NPh) and plasma cell (PLC) modules, followed by a principle component analysis, was used to identify indicator genes per gene signature. Gene signatures were measured in longitudinal samples from two childhood-onset SLE cohorts (n = 101 and n = 34, respectively), and associations with clinical features were assessed. Disease activity was measured using Safety of Estrogen in Lupus National Assessment (SELENA)-SLEDAI. Cluster analysis subdivided patients into three mutually exclusive fingerprint-groups termed (1) all-signatures-low, (2) only IFN high (M1.2 and/or M5.12) and (3) high NPh and/or PLC. All gene signatures were significantly associated with disease activity in cross-sectionally collected samples. The PLC-signature showed the highest association with disease activity. Interestingly, in longitudinally collected samples, the PLC-signature was associated with disease activity and showed a decrease over time. When patients were divided into fingerprints, the highest disease activity was observed in the high NPh and/or PLC group. The lowest disease activity was observed in the all-signatures-low group. The same distribution was reproduced in samples from an independent SLE cohort. The identified gene signatures were associated with disease activity and were indicated to be suitable tools for stratifying SLE patients into groups with similar activated immune pathways that may guide future treatment choices.